The drugmakers Pfizer and Flynn Pharma have been fined a total of £70m for overcharging the NHS for a life-saving epilepsy drug.
The UK’s competition watchdog fined New York-based Pfizer £63m and imposed a £6.7m penalty on Flynn, a smaller UK pharmaceutical firm based in Stevenage. Both companies said they would appeal.
The fines are the result of an in-depth investigation carried out by the Competition and Markets Authority (CMA), which concluded that Pfizer and Flynn charged “unfairly high prices” for phenytoin sodium capsules for more than four years.
The firms de-branded the drug, previously known as Epanutin, and sold it as a generic. That meant it was no longer subject to price regulation and they could set prices at their discretion.
The CMA said because Pfizer and Flynn were the dominant suppliers of the drug in the UK at the time, the NHS had no choice but to pay the inflated price for the important anti-epilepsy medicine.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
